Inhalational monkeypox virus infection in cynomolgus macaques by Roy E. Barnewall et al.
ORIGINAL RESEARCH ARTICLE
published: 17 September 2012
doi: 10.3389/fcimb.2012.00117
Inhalational monkeypox virus infection in cynomolgus
macaques
Roy E. Barnewall*, David A. Fisher , Ashley B. Robertson , Pauline A. Vales , Katherine A. Knostman
and John E. Bigger
Battelle, Columbus, OH, USA
Edited by:
Douglas S. Reed, University of
Pittsburgh, USA
Reviewed by:
Douglas S. Reed, University of
Pittsburgh, USA
Aysegul Nalca, US Army Medical
Research Institute of Infectious
Diseases, USA
*Correspondence:
Roy E. Barnewall, Inhalation
Technologies and Aerobiology,
Battelle, 505 King Avenue,
Columbus, OH 43201, USA.
e-mail: barnewallr@battelle.org
An inhalation exposure system was characterized to deliver aerosolized monkeypox virus
(MPXV), and a non-human primate (NHP) inhalation monkeypox model was developed in
cynomolgus macaques. A head-only aerosol exposure system was characterized, and two
sampling methods were evaluated: liquid impingement via an impinger and impaction via
a gelatin filter. The aerosol concentrations obtained with the gelatin filter and impinger
were virtually identical, indicating that either method is acceptable for sampling aerosols
containing MPXV. The mass median aerodynamic diameter (MMAD) for individual aerosol
tests in the aerosol system characterization and the NHP study ranged from 1.08 to
1.15µm, indicating that the aerosol particles were of a sufficient size to reach the alveoli.
Six cynomolgus macaques (four male and two female) were used on study. The animals
were aerosol exposed with MPXV and received doses between 2.51 × 104 to 9.28 × 105
plaque forming units (PFUs) inhaled. Four of the six animals died or were euthanized
due to their moribund conditions. Both animals that received the lowest exposure doses
survived to the end of the observation period. The inhalation LD50 was determined to
be approximately 7.8 × 104 pfu inhaled. These data demonstrate that an inhalation MPXV
infection model has been developed in the cynomolgus macaque with disease course and
lethal dose similar to previously published data.
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INTRODUCTION
Smallpox, caused by the variola virus, a member of the Poxviridae
family, is a highly contagious and debilitating systemic disease
that is lethal to approximately 25% of its victims (Fenner et al.,
1988, 1989). The World health Organization (WHO) initiated in
1959 a global operation to eradicate smallpox through vaccina-
tion, with the last case reported in 1977. Smallpox was officially
considered eradicated in 1980 (Fenner et al., 1988; Henderson
et al., 1999), but concerns over its use as a biological weapon
have remained (Henderson et al., 1999). Control of a smallpox
outbreak poses significant challenges to first responders and local
and national health care systems. There is no FDA-approved treat-
ment for smallpox beyond supportive care. The current interna-
tional strategy for control of a smallpox outbreak calls for mass
immunization of the general population with the vaccinia virus
vaccine (CDC Smallpox Response Plan; Executive Summary,
2003). In preparation for this contingency, health care workers
and many in the US military are currently being vaccinated. The
conventional vaccine (ACAM2000) consists of a replicating vac-
cinia virus. Vaccinia vaccination was the cornerstone of the small-
pox eradication campaign, and much of the world was vaccinated
during that effort. However, serious complications are associated
with vaccinia, particularly in immunocompromised individuals,
where the vaccination can lead to serious complications including
death (Lane et al., 1970; Thomas et al., 2008). To control an out-
break today, vaccination of at risk individuals would be enacted.
However, there are certain groups or populations that vaccina-
tion is not recommended due to the risk of adverse reactions to
vaccination (Fulginiti et al., 2003). Immunocompromised indi-
viduals cannot be vaccinated because uncontrolled replication of
the vaccine may result in serious complications including death.
TheNational Institute of Allergy and Infectious Diseases (NIAID)
is directing a major effort to provide a safer vaccine, that may be
offered to a population of individuals who otherwise would not
be eligible to receive the ACAM2000 vaccine. To test the efficacy
of these vaccines, animal models of disease must be developed.
Because smallpox is eradicated and ethical considerations, the
efficacy of treatments and vaccines against smallpox cannot be
determined in humans. Therefore, testing of smallpox therapeu-
tics and new vaccines will require US FDA marketing approval
according to 21 CFR 314 subpart I and 21 CFR 601 subpart
H, known as the Animal Rule. To meet the Animal Rule, well-
characterized animal models of smallpox are required, and a non-
human primate (NHP) smallpox model likely will be required.
Although the variola virus can infect NHPs, it does not result in
a lethal systemic disease. Furthermore, the variola virus exists in
only two repositories in the world and is not available for broad
testing of therapeutics and vaccines.
Monkeypox virus (MPXV) is also a member of the
Orthopoxvirus genus and presents a surrogate model for char-
acterizing antivirals and vaccines to treat or prevent smallpox.
Humans can be infected withMPXV, and the clinical presentation
Frontiers in Cellular and Infection Microbiology www.frontiersin.org September 2012 | Volume 2 | Article 117 | 1
CELLULAR AND INFECTION MICROBIOLOGY
Barnewall et al. Inhalational monkeypox infection macaque model
is similar to classic smallpox (Ladnyj et al., 1972; Parker et al.,
2007; Chapman et al., 2010; Damon, 2011). Therefore, MPXV
fulfills both criteria for a relevant smallpox surrogate: (1) it is a
related virus that can infect an NHP and (2) it causes a lethal
systemic infection.
When developing an animal model, it is important that the
experimental route of infection be the same or similar to the
anticipated route of infection in human disease. Transmission of
smallpox occurs from aerosols from close contact with an infected
individual. These infectious droplets can implant onto the nasal,
oral, or pharyngeal mucous membranes or in the alveolar space of
the lung and cause disease (Fenner et al., 1988). Therefore, infec-
tion is likely to occur anywhere along the respiratory tract. There
have been several efforts to develop an NHP model of smallpox
using the MPXV. One of the first well-described efforts involved
the intravenous route of infection. This approach bypassed the
early respiratory events, yet produced the severe systemic disease
symptoms typically observed in human smallpox. This model has
been used to test antiviral drug candidates (Huggins et al., 2009).
Alternatives to the intravenous model have also been examined
that include intratracheal, intranasal, and inhalation. The intra-
tracheal method of exposing cynomolgusmacaques toMPXVwas
recently described (Stittelaar et al., 2006; Goff et al., 2011). This
approach attached a microsprayer to a bronchoscope for intratra-
cheal infection. Kramski infected marmosets with cowpox virus
that had been isolated from a lethal orthopox virus outbreak in
New World monkeys, termed calpox. Calpox was lethal not only
via the intravenous route but also by the intranasal route, and the
marmosets reproducibly develop symptoms resembling smallpox
in humans (Kramski et al., 2010). Small particle aerosols contain-
ing MPXV have been used to infect the lower respiratory tracts
of cynomolgus macaques (Zaucha et al., 2001; Nalca et al., 2010)
via an inhalational route. These studies were able to replicate the
severe symptoms observed in intravenous infections, but required
specialized equipment to generate aerosols containing MPXV.
In this manuscript, an aerosol exposure system was charac-
terized for aersolizing MPXV and an inhalational infection of
cynomolgus macaques with MPXV is described. The NHP expo-
sure doses were performed with high precision relative to target
dose. The disease presentation was shown to be representative of
human smallpox. Respiratory symptoms and a prodromal period
of infection prior to pox lesion development were observed and
some but not all of the inhalation exposed animals developed
pox lesions. These results corroborated the results obtained by
previous investigators (Zaucha et al., 2001; Nalca et al., 2010).
MATERIALS AND METHODS
ANIMALS
Six specific pathogen free Macaca fascicularis (Cynomolgus)
monkeys (four male; two female) were obtained from a USDA
certified vendor (Covance Labs, Alice, TX). The NHPs were
free of obvious clinical signs of illness or malformations and
tested negative for simian immunodeficiency virus (SIV), simian
T-lymphotrophic virus 1 (STLV-1), macacacine herpesvirus 1
(herpes B virus), simian retrovirus 1 (SRV1) and SRV2, and
for poxvirus antibodies prior to placement on study. The
research was conducted in compliance with the Animal Welfare
Act and followed the principles in the Guide for the Care
and Use of Laboratory Animals from the National Research
Council. Additionally, the research was conducted following
an Institutional Animal Care and Use Committee (IACUC)
approved protocol. The institution where the research was con-
ducted is fully accredited by the Association for the Assessment
and Accreditation of Laboratory Animal Care International
(AAALAC). All MPXV exposed animals were housed within a
Biosafety Level 3 (BSL-3) containment laboratory.
VIRUS PROPAGATION AND QUANTITATION
MPXV (Zaire V79-I-005) strain was obtained from the
Biodefense and Emerging Infections Research Resource
Repository (BEI Resources). Monkeypox viral stocks were
prepared in T-150Vero cell flasks (Diagnostic Hybrids, Inc.,
Athens, OH). The virus was diluted in Eagle’s minimal essential
medium (EMEM, Fisher Scientific) with 5% fetal bovine serum
(FBS, Fisher Scientific) without antibiotics to varying concentra-
tions for use in a nebulizer for aerosol exposure. A virus plaque
assay was used to quantitate the virus in the challenge material,
impinger samples, and gelatin filter samples.
PLAQUE ASSAY
MPXV was enumerated in complete Eagles Minimum Essential
Media (EMEM) with 0.1% gentamycin sulfate and 5% FBS
and warmed to 37◦C. Plaque assays were carried out on plates
containing Vero 76 cells at ≥90% confluency obtained from
Diagnostic Hybids Inc, (Anthens, OH). For each sample, one
hundred mL of each dilution was added to each well of a
twelve-well plate. Plates were incubated for 1 hour in at 37◦C at
5% CO2, rocking plates approximately every 15min. After one
hour, one mL of complete media were added to each well and
incubated for 4 days at 37◦C. On day 3, media were removed from
the plates and stained with 0.5–1mL crystal violet solution for
15min and rinsed with PBS. Once the cells were dry, the number
of plaques were counted.
AEROSOL SYSTEM CHARACTERIZATION
The Battelle large animal aerosol exposure system was charac-
terized for aerosolizing MPXV as determined via Spray Factor
(SF) determination (aerosol conc/nebulizer conc). Three start-
ing nebulizer concentrations (5.55 × 103, 6.94 × 104, and 7.19 ×
105 pfu/mL) were aerosolized in duplicate for 10min. One day of
testing was performed to characterize a head-only aerosol expo-
sure system, and two sampling methods were evaluated. The
aerosol system was operated as described previously (Galloway
et al., 2004; Warren et al., 2011). The aerosol samples were col-
lected by two methods head-to head in parallel: (1) into a glass
impinger (Model 7541, Ace Glass Inc., Vineland, NJ) filled with
approximately 20mL of EMEM with one drop of anti-foam A
(Dow Corning, Midland, MI) or (2) by impaction onto a 47mm
gelatin filter (Sartorius, Bohemia, NY). The aerosol particle size
was determined during each test using an Aerodynamic Particle
Sizer® (APS) spectrometer, model 3321 (TSI, Shoreview, MN).
After sampling, each filter was dissolved into 10mL of EMEM
for quantification of MPVX. The impinger and gelatin filter sam-
ples were enumerated by the plaque assay method to quantify
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the MPXV counts per milliliter. The enumeration results, along
with the volume used to dissolve the filter, sampling rate, sam-
ple volume, and sampling duration, were used in the calculation
of the aerosol concentration expressed as plaque forming units
(PFUs)/L of air (see section “Inhaled Dose Calculation”).
ANIMAL AEROSOL EXPOSURES
The Battelle large animal exposure system was used to expose
animals individually, using a flow through design (Galloway
et al., 2004; Warren et al., 2011). Four target exposure doses
of 3.0 × 104, 1.0 × 105, 3.0 × 105, and 9.0 × 105 pfu of MPXV
were delivered to the six monkeys. Briefly, each NHP was anes-
thetized by intramuscular injection of Telazol (tiletamine HCl
and zolazepam HCl) at approximately 3mg/kg. Each NHP was
placed into a biological safety cabinet III (BSCIII) and loaded
into a plethysmograph. Body plethysmography was performed
real-time using Buxco Biosystems XA (Buxco Research Systems,
Wilmington, NC) while the animal’s head was placed within an
exposure chamber. Air was supplied to the system by an in-
house air system filtered through a carbon filter and two High
Efficiency Particulate Air (HEPA) capsule filters. A modified
Microbiological Research Establishment type three-jet Collison
nebulizer (BGI, Waltham, MA) with a precious fluid jar was used
to generate a controlled delivery of aerosolized MPXV from an
EMEM suspension. The Collison nebulizers are designed to gen-
erate aerosols having an approximate mean diameter of 1–2µm.
Aerosol concentration was determined by analysis of atmospheric
samples drawn from a port on the side of the exposure chamber.
The samples were collected by two methods in parallel: (1) into a
glass impinger (Model 7541, Ace Glass Inc., Vineland, NJ) filled
with approximately 20mL of media or (2) by impaction onto a
47mm gelatin filter (Sartorius, Bohemia, NY). A vacuum pump
pulled the sample into the impinger or filter at 6.0 ± 0.3 L/min.
The virus impacted on the gelatin filter was recovered by dis-
solving the filter in 10mL of EMEM. The filter samples were
enumerated by the plaque assay method to quantify the MPXV
counts per milliliter. The gelatin filter enumeration results, along
with the volume used to dissolve the filter, sampling rate, sam-
ple volume, and sampling duration, were used in the calculation
of the aerosol concentration expressed as pfu/L of air (see section
“Inhaled Dose Calculation”).
PLETHYSMOGRAPHY
Body plethysmography was performed real-time on each animal
during agent exposure to measure important respiratory param-
eters. These parameters (tidal volume, total accumulated tidal
volume or TATV, and minute volume) were calculated from the
Buxco XA software by the measured volumetric displacement of
air caused by the movement of the thoracic cavity of an ani-
mal while it was in the plethysmograph. The data generated for
each animal was used to determine the TATV, which along with
the aerosol concentration was used in calculating the inhaled
dose. The plethysmograph was connected to a pneumotach (Hans
Rudolph, Inc., Kansas City, MO) that was attached to a differ-
ential pressure transducer (Model DP-45; Validyne Engineering
Corp., North Ridge, CA). Pressure differential measurements
from inhalations and exhalations were transmitted to Biosystems
XA software that calculated and recorded respiratory function.
Prior to animal exposures, the plethysmography system was cal-
ibrated to establish unit (baseline) and air volume displacements
from 5 to 40mL to simulate animal respiration. This calibration
was performed to encompass the respiration volume range of the
animal model for accurate TATV measurements.
CLINICAL OBSERVATIONS AND SAMPLES
Clinical observations of each NHP were recorded twice daily for
21 days post-exposure. Body temperatures were collected once
daily from two transponders (shoulder and hip) beginning two
days prior to exposure through the end of study. Body weights
were collected on Days 0, 2, 4, 6, 10, 14, 18, and 21 days post-
exposure. Blood and buccal swabs for virus quantification by
qPCR were collected on Days 0, 2, 4, 6, 10, 14, 18, and 21
post-virus challenge. The blood was collected in EDTA tubes,
200–400µL. Lesion counts were obtained on Days 0, 2, 4, 6,
10, 14, 18, and 21 post-exposure. The weights, temperature, and
lesion counts were tabulated on a Clinical Assessment form on
Days 0, 2, 4, 6, 10, 14, 18, and 21 to aid in clinical monitoring.
NECROPSY AND HISTOPATHOLOGY
Necropsies were performed on all NHPs, and tissues collected for
histology. Protocol-required tissue samples (brain, heart, lungs,
and gross lesions) were placed in 10% neutral buffered forma-
lin, processed to approximately 5-micronH&E-stained slides, and
examined microscopically by an ACVP board-certified pathol-
ogist. Gross and microscopic diagnoses were entered into the
PATH/TOX SYSTEM (Xybion Medical Systems Corporation) for
data tabulation and analysis. Tissues from all NHPs were exam-
ined microscopically. Microscopic findings were graded semi-
quantitatively according to the following scale, with the associated
numerical score used to calculate average severity grades for each
lesion by group and sex. Minimal (Grade 1) represented the least
detectible lesion; mild (Grade 2) represented an easily discernible
lesion; moderate (Grade 3) represented a change affecting a large
area of the represented tissue; and marked (Grade 4) represented
a lesion that approached maximal.
INHALED DOSE CALCULATION
The total inhaled dose (Dinh) was calculated from the gelatin fil-
ter sample concentration (C), sampling parameters, total inhaled
tidal volume (Vinh) and exposure duration (T) according to the
equation below. The total number ofMPXV captured during each
exposure was the product of the gelatin filter concentration (Ci)
and the volume the filter was dissolved in (C × V). The total
number of PFUs was divided by the amount that was sampled
through the filter during the exposure time (S × T). The aerosol
concentration was (C × V) (S × T)−1. The inhaled dose was the
product of the aerosol concentration multiplied by the TATV
measured during plethysmography as detailed in Equation 1:
Dinh =
[
(C × Vi) (S × T)−1
] × (Vinh) = Ca × Vinh
Dinh = Total inhaled dose (PFU)
C = Filter sample concentration (PFU/mL)
Vi = Filter sample volume (mL)
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S = Filter sampling rate (L/min)
T = Exposure time (min)
V inh = Total inhaled tidal volume (L), as determined by plethys-
mography
Ca = Aerosol concentration (PFU/L)
STATISTICAL ANALYSIS
Statistical analysis for the LD50 for the inhaled dose data was fitted
to a logistic regression model to survival probability as a func-
tion of base-10 logarithm of the measured aerosol dose. Since the
two lowest dose animals survived, and the four higher dose ani-
mals succumbed, a conventional logistic regression model such as
Spearman-Karber would provide an indeterminate result. Thus,
a logistic regression procedure that used a penalized maximum
likelihood (Firth, 1993) was implemented in Stata 11.1 using
the “firthlogit” command. The model fit to the data was this
approximate equation:
In[Probability of Survival/(1 − Probability of Survival)]
= −17.27 + 3.53 × log10(Measured Dose)
NUCLEIC ACID ISOLATION AND QUANTITATIVE POLYMERASE
CHAIN REACTION (qPCR)
Nucleic acid isolation
Lung, brain, and heart samples from each animal were homoge-
nized in 1mL of phosphate buffered saline (PBS). Total nucleic
acid was isolated from whole blood samples (100µL) using
the Specific B protocol on a NucliSens® easyMAG™ instrument
(BioMérieux, l′Etoile, France). The homogenate was then poured
through a 40µM cell strainer, with the homogenizer and cell
strainer rinsed with a total of 2mL of NucliSens easyMAG Lysis
Buffer. Buccal swabs were placed in a 1mL solution consisting of
97% PBS, 2% FBS, and 1% Penicillin/Streptomycin. The entire
recoverable volume of the solution was then added to 2mL of
NucliSens Lysis Buffer. Whole blood was collected into ETDA
tubes, with 100µL taken and added to 2mL of NucliSens Lysis
Buffer. Total nucleic acid was then isolated from these lysates
using the NucliSens easyMAG. In brief, easyMAGMagnetic Silica
is added to each sample after loading the lysate into sample vessels
in the instrument. The Magnetic Silica then binds total nucleic
acid during a 10min incubation at room temperature, and the
Magnetic Silica is then collected, and subsequently washed twice
with NucliSens easyMAG Extraction Buffer 1, then twice with
NucliSens easyMAG Extraction Buffer 2, and once with NucliSens
easyMAG Extraction Buffer 3, with a final elution of total nucleic
acid in 50µL of NucliSens easyMAG Extraction Buffer 3.
Total nucleic acid was isolated from whole blood samples,
throat swabs and homogenized tissues using the Specific B pro-
tocol on a NucliSens® easyMAG™ instrument (BioMérieux)
according to manufacturer’s methods.
Quantitative Real-Time PCR (qRT-PCR)
Total purified nucleic acid was eluted in a final volume of 40µL.
Each nucleic acid sample was assayed by qRT-PCR for the MPXV
N3R gene in duplicate on a 7900HT real-time PCR system
(Applied Biosystems, Life Technologies Corp., Carlsbad, CA).
Each 25µL reaction contained 5µL of sample with the remain-
ing volume consisting of TaqMan® Gene Expression Master
Mix (2X, Applied Biosystems), sterile water, and a custom gene
expression assay (Applied Biosystems) consisting of previously
developed primers and a 3′-minor groove binding probe spe-
cific for a portion of the MPXV N3R gene (Kulesh et al., 2004).
The final concentration of primers and probe were 900 nM and
250 nM, respectively. Thermal cycling on the 7900HT instrument
was as follows: 50◦C for 2min, 95◦C for 10min, followed by 45
cycles of 95◦C for 15 sec and 60◦C for 1min. A plasmid contain-
ing a cloned insert of the primer and probe specific portion of
the N3R gene (Retrogen, Inc.) was run as a 10-fold serial dilution
(2 × 107 to 2 copies/µL) reference standard curve with all samples
to determine the concentration of gene copies in each sample. The
final concentration for each sample was reported as copies per
milliliter of original sample. The sequence of the primers, probe,
and amplicon are as follows:
Forward Primer: AACAACCGTCCTACAATTAAACAACA
Reverse Primer: CGCTATCGAACCATTTTTGTAGTCT
Probe: 6FAM-TATAACGGCGAAGAATATACT-NFQ
Amplicon: AACAACCGTCCTACAATTAAACAACAttactttTATA
ACGGCGAAGAATATACTgaaattgatagatcgaaaaaagccactaataaaaa
cagttggttaattacttcaggctttAGACTACAAAAATGGTTCGATAGCG
RESULTS
AEROSOL SYSTEM CHARACTERIZATION
The virus aerosol was characterized by conducting two 10-min
sprays at three concentrations. Figure 1 shows the comparisons
of the impinger and gelatin filter samplings of the aerosol cham-
ber during these characterization experiments. The aerosol con-
centrations obtained with the filter compared to the impinger
were virtually identical, indicating that either method is accept-
able for sampling aerosols containing MPXV (Figure 1). Figure 1
indicates that there was a linear increase in the aerosol con-
centration as the starting nebulizer concentration was increased.
Additionally, Figure 1 shows that the SF was relatively constant
among the nebulizer concentrations tested, with a mean value of
2.4 × 10−6 for the impinger and 3.0 × 10−6 for the gelatin fil-
ter. As a result, gelatin filter results were used in the animal dose
calculations. The aerosol contained particles with mass median
aerodynamic diameter (MMAD) of 1.10µm and ranged from
1.08–1.15µm for each individual test, and the geometric stan-
dard deviation (GSD) was 1.61µm with a range of 1.58–1.64µm
for each individual test. These results indicated that the aerosol
distribution was relativelymonodispersed and contained particles
capable of reaching the deep lung in animal testing (Schlesinger,
1985).
The SF can be used as a fundamental indicator to measure and
assess the performance of the aerosol system over time (i.e., when
operating the aerosol system under the same conditions, mean SF
should be the same or fall within the same range time after time).
The SF is the ratio of the concentration of agent in the aerosol
(aerosol concentration) to the starting concentration used in the
aerosol generator. As a consequence, the SF value is a unitless fac-
tor that represents the dilution that is to be expected during an
aerosol experiment using the same bio-agent in the same aerosol
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FIGURE 1 | Shows the results of the monkeypox virus aerosol
concentrations (Ac) for the gelatin filter compared to the impingers.
It also shows the Spray Factor (SF) results for the gelatin filter compared to
the impinger. The aerosol concentrations were equivalent by impingement
and gel filtration capture, they were proportional to the starting nebulizer
concentration, and there was no difference in the Spray Factor Values
between the gelatin filter and impinger.
system under the same conditions. This enables the assessment of
the performance of the aerosol exposure process and whether it is
stable (the same) for each individual test or exposure within a test
day and across multiple test days.
AEROSOL EXPOSURES OF NHPs
Following the aerosol characterization, the aerosol system was
used to expose six cynomolgus macques to nebulized MPXV. The
actual inhaled exposure dose was calculated for each animal by
multiplying the actual inhaled air volume of the animal while in
the aerosol chamber (as measured by realtime plythesmography)
against the aerosol chamber’s virus concentration as measured by
gelatin filtration. Table 1 is a summary of the target doses com-
pared to the actual exposure dose received by each NHP along
with the day post-exposure the animal died or was euthanized.
The actual exposure doses were well within the assay confi-
dence of the targeted doses. The aerosol contained particles with
MMAD of 1.07µm and ranged from 1.06–1.09µm for each indi-
vidual test and the GSD was 1.58 with a range of 1.56–1.70 for
each individual test.
CLINICAL FINDINGS
Table 2 is a summary of the cutaneous lesions that developed
on the animals during the post-exposure observation period.
Lesion presentation began 6 days following exposure, and then
only on the two highest dosed animals. Animal A08407 suc-
cumbed without apparent lesion presentation. Animal C0404035
was the only animal to present with severe lesions. Animal A08407
died 8 Days post-exposure, and at necropsy and histopathol-
ogy presented with pneumonia and intrunuclear inclusion bodies
consistent with pox infection. Death was likely from pneumonia
before secondary viremia and associated skin lesions.
Virus burden in this study was measured by qPCR quan-
tification of virus from tissues taken at necropsy and by qPCR
quantification of virus in buccal swabs and whole blood taken
every other day during the first 10 days after exposure. Low levels
of virus were detected in buccal samples on Day 4 in one ani-
mal and in the blood of four animals. By Day 6 all animals had
detectable levels in the blood and four out of six had detectable
levels in buccal samples (Table 3), suggesting that detection of
virus in saliva was dependent upon hematogenous spread of virus
and most likely from the lungs. In the two animals that survived
to end of study, virus was detected at extremely low levels, if at all,
in blood and saliva after Day 14.
Dose dependent virus shedding in saliva or viremia was not
readily apparent, though the animal that received the highest
exposure dose (C0404035) did appear to have higher blood and
saliva virus titers than any others on any given day.
As expected, the highest virus titers were found in lung tissues
at necropsy (Table 3) as this was the site of dosing and initial
infection. Interestingly, Animal C0501065, which was still show-
ing clinical signs of illness, survived and was recovering at the end
of in-life testing on Day 21 post-exposure. The animal no longer
Table 1 | Exposure dose summary.
Animal ID Sex Weight (kg) Targeted exposure dose (pfu) Actual exposure dose (pfu) Day of death or euthanasia∗
C0412403 Male 8.0 3.00 × 104 4.25 × 104 −
C0501065 Male 8.7 3.00 × 104 2.51 × 104 −
A08407 Female 2.5 1.00 × 105 1.22 × 105 8
C0506081 Male 9.1 1.00 × 105 2.85 × 105 9*
A09166 Female 3.0 3.00 × 105 3.90 × 105 7
C0404035 Male 10.1 9.00 × 105 9.28 × 105 10
*Animal found dead; all others euthanized/euthanized moribund.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org September 2012 | Volume 2 | Article 117 | 5
Barnewall et al. Inhalational monkeypox infection macaque model
Table 2 | Lesion count summary.
Animal ID Actual exposure dose (pfu) Lesion count (arms, legs, ventral, head)a
Day 0 Day 2 Day 4 Day 6 Day 8 Day 10
C0412403 4.25 × 104 0 0 0 0 0 1, 1, 1, 1
C0501065 2.51 × 104 0 0 0 0 0 1, 1, 1, 1
A08407 1.22 × 105 0 0 0 0 0 –
C0506081 2.85 × 105 0 0 0 0 0 (1, 1, 1, 1)b
A09166 3.90 × 105 0 0 0 0, 1, 1, 0 – –
C0404035 9.28 × 105 0 0 0 1, 2, 2, 2 1, 3, 3, 3 3, 3, 3, 3
aLesion count : 1, <25 lesions; 2, 25–99 lesions; 3, >99 lesions.
bObservation taken on Day 9 at euthanasia.
Table 3 | Summary of blood, buccal, and tissue qPCR results.
Animal ID Day 0 Day 2 Day 4 Day 6 Day 8 Day 10 Day 14 Day 18 Day 21
BLOOD
C0412403 LLOQ LLOQ 5.1 × 103 7.0 × 104 1.5 × 105 4.0× 105 3.1 × 105 1.2 × 103 LLOQ
C0501065 LLOQ LLOQ LLOQ 7.4 × 104 3.0 × 105 2.6× 105 4.1 × 104 LLOQ LLOQ
A08407 LLOQ LLOQ 7.8 × 103 1.8 × 105 2.7 × 105 NA NA NA NA
C0506081 LLOQ LLOQ LLOQ 9.1 × 104 3.6 × 105 NA NA NA NA
A09166 LLOQ LLOQ 9.3 × 103 4.8 × 105 NA NA NA NA NA
C0404035 LLOQ LLOQ 2.5 × 104 6.9 × 105 4.5 × 106 4.8× 106 NA NA NA
BUCCAL SWABS
C0412403 LLOQ LLOQ LLOQ 2.5 × 103 1.1 × 105 2.5× 105 1.1 × 105 6.3 × 103 8.5 × 102
C0501065 LLOQ LLOQ LLOQ LLOQ 1.4 × 105 4.1× 105 6.9 × 104 3.5 × 103 3.7 × 103
A08407 LLOQ LLOQ LLOQ LLOQ 3.0 × 104 NA NA NA NA
C0506081 LLOQ LLOQ LLOQ 8.4 × 102 2.1 × 105 NA NA NA NA
A09166 LLOQ LLOQ 3.2 × 102 9.0 × 103 NA NA NA NA NA
C0404035 LLOQ LLOQ 5.3 × 103 5.8 × 104 1.9 × 106 4.6× 106 NA NA NA
Animal ID Lung Brain Heart Day of death
C0412403 LLOQ LLOQ 3.7 × 102 21
C0501065 6.5 × 106 LLOQ LLOQ 21
A08407 1.8 × 106 LLOQ 4.0 × 103 8
C0506081 3.5 × 104 4.3 × 102 4.1 × 103 9
A09166 2.2 × 108 1.3 × 103 2.8 × 104 7
C0404035 1.2 × 108 3.2 × 103 2.1 × 104 10
NA, not applicable; LLOQ, below lower limit of quantification (200 copies/g tissue; 1000 copies/mL blood, 200 copies/mL swab). Results reported as genomes/mL
or genomes/g tissue.
presented with virus in its blood and saliva but still showed 6
logs of virus genome in its lungs Day 21 post-infection. This is
in contrast to animal C041203, which had no detectable virus in
its lung, and only minimal amounts in its heart.
GROSS NECROPSY AND HISTOPATHOLOGY
Both monkeys in the targeted 3 × 104 pfu/animal group survived
to the study end on Day 21 post-exposure. These animals had
grossly evident skin pocks on multiple body sites but no internal
gross lesions. All four monkeys exposed to higher concentra-
tions of MPXV died or became moribund and were euthanized
between study Days 7–10. Lung discoloration, bronchial lymph
node enlargement, and/or skin pocks were evident in three of the
four monkeys, while one lacked any gross lesions. All gross lesions
noted were typical of monkeypox.
All monkeys that succumbed or became moribund during
the study had microscopic lesions consistent with monkeypox.
Lesions included surface (skin) and respiratory epithelial necrosis
and reactive epithelial hyperplasia, with some epithelial cells in
both sites containing eosinophilic to amphophilic intranuclear
and/or intracytoplasmic inclusion bodies (virus inclusions).
Fibrinosuppurative inflammation, edema, hemorrhage, and lym-
phoid necrosis were evident in the skin, tongue, lungs, and/or
bronchial lymph nodes. Specifically, lung lesions had a prominent
bronchial/peribronchial airway pattern (bronchopneumonia)
indicative of the inhalation route of infection, as well as a slightly
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more subtle perivascular to interstitial pattern, consistent with a
septicemic phase.
STATISTICAL ANALYSIS
The median lethal dose (LD50) and LD90 were estimated to be
77,900 pfu and 326,000 pfu, respectively. These results are simi-
lar to those reported in the recent literature (Nalca et al., 2010).
The logistic regression model did not have a statistically signif-
icant slope (p = 0.18), so 95% Fieller’s confidence intervals for
these percentiles are not bounded. The reason the 95% confidence
intervals are not bounded is due to the small number of animals
tested and because the two animals that received the lowest doses
survived and the four higher doses animals died. Figure 2 is a plot
showing the survival data as well as the logistic regression curve
fit to the data.
DISCUSSION
Infection of pox virus by different exposure routes will lead to
variations in the course of disease in NHPs and humans (Hahon,
1961; Reynolds et al., 2006; Chapman et al., 2010). The inhalation
route of infection is preferred in an animal model as this closely
resembles the natural route of infection in human smallpox
(Hahon, 1961; Henderson et al., 1999). As a result, the inhala-
tion MPXV model in the cynomolgus macaque was developed
and characterized.
The initial step was the characterization of MPXV in the
inhalation exposure system. The aerosol exposure system charac-
terization testing indicated that the aerosol concentrations deter-
mined by impingement and gel filtration capture were equivalent
and were proportional to the starting nebulizer concentration.
Also, there was no difference in the SF values between the gelatin
filter and impinger. The results from the characterization testing
were used to determine the starting concentration needed in the
nebulizer to achieve the desired target doses to the NHPs by use
of the SF.
FIGURE 2 | Survival Data Logistic Regression Curve showing the
survival data as well as the logistic regression curve fit to the data.
Dashed lines represent the 95% confidence intervals.
The doses delivered to the NHPs were very close to the desired
targetdoses, indicating that theaerosol exposure systemperformed
identically to the characterization day, and suggest low system
variability both within-a-day and between-days. The difference
in the SF value between impingers and gelatin filters was 20% or
lower at the nebulizer concentrations tested and is well within the
0.5 log variability of plaque assay enumerationmethod, indicating
that the values are essentially the same. Although the one day
of SF characterization testing produced excellent results, ideally
at least three days of characterization testing is recommended
to be performed along with a larger number of replicates at
each concentration tested. This would enable the determination
of a more accurate and reliable with-a-day and between-day
variability so that the variability of doses delivered to an animal
could be more accurately predicted in future animal testing.
Accounts from other facilities have shown that NHPs that suc-
cumb to lethal aerosolized MPXV do so via severe respiratory
disease (Zaucha et al., 2001; Chapman et al., 2010), and recently
some are reported without presentation of typical pox skin lesions
(Nalca et al., 2010). This observation was also noted in the cur-
rent study and was reflected in the presentation of disease and
death of three of the four NHPs that succumbed on this study.
Animals C0506081 and A09166 died with few pox lesions, and
A08407 had no pox lesions evident. This is in contrast to the intra-
venous lethal exposure model where the NHP succumbs to severe
systemic monkeypox disease with total body coverage of lesions
(Chapman et al., 2010).
The NHPs succumbed to infection in a dose-dependent fash-
ion, with the lowest dose group surviving exposure. The animals
succumbed due to respiratory disease, as reflected by the amount
of virus recovered from the lungs, as compared to other organs
(see Table 3) and the lesions in the lung.
The mortality data suggest that weight and/or NHP sex
may be a contributing factor to this infection model. Two
males, weight ≥8 kg, survived exposure with 3 × 104 pfu mon-
keypox. Further, the two other males (weight ≥9 kg) that received
9 × 105 pfu and 1 × 105 pfu survived longer than the two females
(weight ≥3 kg). This question can only be resolved by conducting
a well controlled age/weight/sex comparison study. To mitigate
this potential affect, special consideration should be given to the
size, age and sex of animals placed on future studies.
Virus in blood and buccal samples was detected as early as
day 4 post-aerosol challenge and peak between days 6 and 10,
which corroborates what has been observed by other investigators
(Nalca et al., 2010).
Multiple objectives were fulfilled from these tests. An aerosol
exposure system was characterized using aerosolized MPXV, and
it was shown that gelatin filters and impingers of type model
7541 generated equivalent enumeration results when sampling
the MPXV aerosol. Following characterization of the aerosol
exposure system, an NHP inhalation study determined a lethal
exposure dose of MPXV, and an inhalation cynomolgus macaque
model of MPXV infection was developed. Actual NHP expo-
sures were performed with high precision relative to target dose,
and the lesions and lethality were similar to the previously pub-
lished data for the cynomolgus monkey (Zaucha et al., 2001,
Nalca et al., 2010).
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